FLEX Company

For medtechs, the short term has become complicated almost beyond imagination, with markets and trade disrupted by geopolitical conflict, tariffs, and supply chain difficulties and even the Suez Canal

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Bluebird Will Use Inhibrx’s

Investors can't get enough of companies that are developing drugs to treat non-alcoholic steatohepatitis (NASH), more than doubling the value of two small biopharmaceutical firms based on recent mid-s

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer